Conference Correspondent

Exploring AONN+ National Evidence-Based Navigation Metrics Outcomes at ACCC
Highlights From ACCC, Conference Correspondent, AONN+ Standardized Metrics
Web Exclusives — March 20, 2020

Danelle Johnston, MSN, RN, HON-ONN-CG, OCN, and Tricia Strusowski, RN, MS, recapped their recent presentation from the ACCC 46th Annual Meeting & Cancer Center Business Summit, in which they discussed the National Evidence-Based Oncology Navigation Metrics: Multisite Exploratory Study to Demonstrate Value and Sustainability of Navigation Programs. The study was launched in June 2018 as a collaborative effort between the Academy of Oncology Nurse & Patient Navigators (AONN+), Chartis Oncology Solutions, and the American Cancer Society (ACS).

Genetics, Genomics, and You: A Primer for Oncology Navigators
AONN+ Conference Highlights, Conference Correspondent
April 2019 Vol 10, No 4 — April 8, 2019
Nurses and navigators play a crucial role in teaching patients about genetics and genomics, as well as in gathering the vital information necessary to actually carry out genetic testing and allowing patients to take control of their genetic inheritance.
What’s Hot and Trending in Oncology Care
AONN+ Conference Highlights, Conference Correspondent
April 2019 Vol 10, No 4 — April 8, 2019
At the 2018 AONN+ Annual Conference, attendees heard a rapid-fire rundown of some of the most newsworthy, and sometimes controversial, topics in cancer care.
The Importance of Trust: Reaching Disparate Populations with Cancer
AONN+ Conference Highlights, Conference Correspondent
March 2019 Vol 10, No 3 — March 20, 2019
Patients with cancer, even in the most “favorable” of circumstances, often face hurdles to care.
Supercharging Your Navigation Program
AONN+ Conference Highlights, Conference Correspondent
March 2019 Vol 10, No 3 — March 20, 2019
Whether an oncology navigation program is just starting out or has already become a well-oiled machine, there are usually a few—or perhaps, quite a few—ways that a navigation program can potentially be improved, according to Lillie D. Shockney, RN, BS, MAS, ONN-CG, Co-Founder and Program Director of the Academy of Oncology Nurse & Patient Navigators (AONN+).
PACIFIC: Practice-Changing Trial in Stage III Unresectable NSCLC
Conference Correspondent, Highlights From IASLC
December 2018 Vol 9, No 12 — December 5, 2018

The PD-L1 inhibitor durvalumab showed an overall survival benefit in patients with unresectable stage III non–small cell lung cancer (NSCLC) in the phase 3 PACIFIC trial.

Two New Therapies Active in NSCLC with EGFR/HER2 Exon 20 Mutations
Conference Correspondent, Highlights From IASLC
Best Practices in Lung Cancer – November 2018 Vol 9 — November 29, 2018
Researchers are chipping away at the genetic subtypes of non–small-cell lung cancer (NSCLC).
Entrectinib Encouraging in ROS1-Positive NSCLC
Conference Correspondent, Highlights From IASLC
Best Practices in Lung Cancer – November 2018 Vol 9 — November 29, 2018
Entrectinib achieved high response rates as well as durable responses in patients with ROS1-positive non–small cell lung cancer (NSCLC), including patients with brain metastases, according to a pooled analysis of phase 1 and 2 trials.
New Regimen for SCLC: Atezolizumab plus Chemotherapy
Conference Correspondent, Highlights From IASLC
Best Practices in Lung Cancer – November 2018 Vol 9 — November 29, 2018
Atezolizumab combined with carboplatin/etoposide represents a new standard of care for first-line treatment of extensive-stage small cell lung cancer (ES-SCLC), according to results from the phase 3 IMpower133 trial presented at the IASLC 19th World Conference on Lung Cancer.
Next-Generation ALK Inhibitor Prolongs Survival vs Crizotinib in ALK+ NSCLC
Conference Correspondent, Highlights From IASLC
Best Practices in Lung Cancer – November 2018 Vol 9 — November 29, 2018
Brigatinib significantly prolonged survival compared with crizotinib (standard of care) as first-line therapy in patients with advanced anaplastic lymphoma kinase (ALK)-positive non–small cell lung cancer (NSCLC).
High Tumor Mutational Burden Predicts Response to Nivolumab plus Ipilimumab Combo in NSCLC
Highlights From AACR, Conference Correspondent, Lung Cancer, NSCLC
Best Practices in Lung Cancer – November 2018 Vol 9 — November 29, 2018
The combination of nivolumab plus ipilimumab extended progression-free survival (PFS) versus stan­dard chemotherapy as first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) with a high tumor mutational burden (TMB).
Home Run: Chemo-Checkpoint Inhibitor Combo in Newly Diagnosed Metastatic NSCLC
Highlights From AACR, Conference Correspondent, Lung Cancer
Best Practices in Lung Cancer – November 2018 Vol 9 — November 29, 2018
A burning question is whether immunotherapy combinations will further improve outcomes over checkpoint inhibitor therapy alone; and if so, which combinations will rise to the top.
Underserved Populations and Their Healthcare Providers Need Better Education About Clinical Trials and Biobanking
Conference Correspondent
June 2018 Vol 9, No 6 — June 12, 2018
People from lower socioeconomic backgrounds, minority groups, and rural areas are not well represented in clinical trials and biobanking, hampering research on health disparities.
Updated Colon and Rectal Cancer Guidelines Include Options for Surveillance and Shortened Duration of Adjuvant Treatment
Conference Correspondent, Highlights From NCCN
May 2018 Vol 9, No 5 — May 22, 2018
The National Comprehensive Cancer Network has overhauled its guidelines for the management of colon and rectal cancers.
Targeted Options for Metastatic NSCLC Expanded in NCCN Guidelines
Conference Correspondent, Lung Cancer, NCCN Guidelines, Highlights From NCCN
May 2018 Vol 9, No 5 — May 22, 2018
The updated guidelines from the National Comprehensive Cancer Network on the management of metastatic non–small cell lung cancer reflect the addition of osimertinib as a first-line option in patients with an epidermal growth factor receptor (EGFR)-sensitizing mutation and as subsequent therapy in patients whose disease progresses following another tyrosine kinase inhibitor if they develop a T790M resistance mutation.
2017 San Antonio Breast Cancer Symposium: Program Highlights
Breast Cancer, Conference Correspondent, Highlights From SABCS
March 2018 Vol 9, No 3 — March 15, 2018
The 40th anniversary of the San Antonio Breast Cancer Symposium was attended by approximately 8000 healthcare professionals and featured presentations ranging from basic science to preliminary clinical trials and new standards of care. Below is a summary of key presentations featured at the press conferences.
CDK4/6 Inhibitors Effective in Older Women, But with More Side Effects
Breast Cancer, Conference Correspondent, Highlights From SABCS
March 2018 Vol 9, No 3 — March 15, 2018
Older patients with hormone receptor–positive, HER2-negative, metastatic breast cancer derive similar benefit as younger patients treated with CDK4/6 inhibitors as part of initial endocrine therapy, according to a pooled analysis of registration trials presented at the 2017 San Antonio Breast Cancer Symposium.
Sexual Health Key Concern for Women Cancer Patients
Conference Correspondent
December 2017 Vol 8, No 12 — December 6, 2017
At the 2017 Annual Meeting of the Multinational Association of Supportive Care in Cancer, Dr. Jeanne Carter shared research from her program at MSKDD to update attendees on current finding, newer assessment instruments, and clinical tools to identify sexual health concern in women with cancer.
New Devices Prevent Chemotherapy-Induced Hair Loss
By Julie R. Nangia, MD
Conference Correspondent, Side-Effects Management
Best Practices in Breast Cancer – October 2017 Vol 8 — October 18, 2017
Scalp cooling devices that allow patients treated with chemotherapy to retain their hair are used more commonly in Europe than in the United States, but this may be about to change now that the FDA has approved 2 scalp cooling devices: the DigniCap (approved in 2015) and the Paxman scalp cooling device (approved in 2017).
At the Heart of Survivorship Is “Person-Centered Care”
Conference Correspondent, Highlights From IASLC, Survivorship
March 2017 Vol 8, No 3 — March 7, 2017
In the delivery of survivorship programs, oncology nurses have a duty to the person as whole, not just to their cancer.
Preoperative Thoracic Surgery Education Improves Patient Outcomes
Conference Correspondent, Highlights From IASLC
March 2017 Vol 8, No 3 — March 7, 2017
Preoperative thoracic surgery education increases patient satisfaction and decreases patient anxiety and readmission rates associated with postoperative complications, all while optimizing overall outcomes for thoracic surgery patients, according to Katherine O. Kuhns, CRNP, a nurse practitioner specialist in thoracic surgery at the University of Pennsylvania Penn Presbyterian Medical Center.
eHealth and Supportive Care in Thoracic Oncology
Conference Correspondent, Highlights From IASLC
March 2017 Vol 8, No 3 — March 7, 2017
Remote monitoring can improve quality of care and patient outcomes in the management of people with cancer, according to Roma Maguire, PhD, MSc, BN, RGN.
Nurses Play a Vital Role in Supportive Care for Patients Receiving Systemic Therapy
Conference Correspondent, Highlights From IASLC
March 2017 Vol 8, No 3 — March 7, 2017
Progress has been made in lung cancer treatment, but as patients are living longer, addressing the toxicities of their systemic therapy is becoming increasingly paramount. In this field of patient management, oncology nurses play a vital role, according to Tanja Cufer, MD, PhD, a medical oncologist and Professor of Oncology at Medical Faculty, University of Ljubljana, Slovenia, and Senior Counselor at the University Clinic in Golnik, Slovenia.
The Role of Nurses in Providing Psychosocial Support for Lung Cancer Patients
Conference Correspondent, Highlights From IASLC, Lung Cancer
March 2017 Vol 8, No 3 — March 7, 2017
Around 80% of lung cancer patients experience some level of psychological distress, but regardless of the availability of psychosocial services, nurses can employ simple interventions to reduce the psychological distress of patients and improve their quality of life, according to Andreja C. Skufca-Smrdel, MSc, a clinical psychologist and psychotherapist in the Department of Psycho-oncology at the Institute of Oncology in Ljubljana, Slovenia.
Long-term Care of Lung Cancer Patients: A Novel Thoracic Survivorship Program
Conference Correspondent, Highlights From IASLC, Lung Cancer
February 2017 Vol 8, No 2 — February 13, 2017
Lung cancer patients experience considerable physical and psychosocial sequelae of their treatment in addition to preexisting comorbidities, but there are many opportunities to intervene through surveillance, screening, and management delivered as part of a survivorship program, according to James Huang, MD, a thoracic surgeon at Memorial Sloan Kettering Cancer Center (MSKCC) in New York, NY.
Spiritual Care of Cancer Patients Across the Continuum
Highlights From ACCC, Conference Correspondent
December 2016 Vol 7, No 11 — November 28, 2016
A report from the Association of Community Cancer Centers encouraging spiritual care plans for patients.
Call to Action: Address Patients’ Sexual Health
Highlights From ASTRO, Conference Correspondent
November 2016 Vol 7, No 10 — November 2, 2016
Sexual dysfunction is a common problem for cancer survivors, and nurses can be a part of the solution by addressing this issue, educating themselves, and joining with other health professionals who care about patients’ sexual health.
ASCO 2016 Annual Meeting
Highlights From ASCO, Conference Correspondent
August 2016 Vol 7, No 7 — August 3, 2016
More than 30,000 healthcare professionals from around the world attended the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago, IL.
Navigation “Refresher” Provided by Lillie D. Shockney, RN, BS, MAS
Highlights From ASCO, Conference Correspondent, Navigation
August 2016 Vol 7, No 7 — August 3, 2016
With patient navigation now established as a valuable component of cancer care, most providers understand what “navigation” means, but fresh insights such as those provided by a veteran of navigation, Lillie D. Shockney, RN, BS, MAS, are welcomed.

Page 1 of 2

Journal of Oncology Navigation & Survivorship

Contact Us | Editorial Board

Amplity

© Amplity, Inc. All rights reserved.

Connect with Us

 
 
JONS

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
    Profession or Role
    Primary Specialty or Disease State
    Country

Back to Top

Amplity © Amplity, Inc. All rights reserved.